Disorder of pilosebaceous unit
MONDO:0002917A disease that involves the pilosebaceous unit.
Also known as: disease of pilosebaceous unit, disease or disorder of pilosebaceous unit, disorder of pilosebaceous unit, hair and hair follicle diseases, hair disorder, hair/hair follicle diseases, pilosebaceous unit disease, pilosebaceous unit disease or disorder
341 clinical trials for this condition and its sub-types, 7 tagged with Disorder of pilosebaceous unit itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Disorder of pilosebaceous unit
-
Hair anomaly 0 trials · 228 incl. sub-types
8 sub-types
- Alopecia 130 trials · 225 incl. sub-types Sub-types →
- Pili bifurcati 2 trials
- Ringed hair disease 1 trial
- Isolated familial wooly hair disorder 0 trials Sub-types →
- Pili gemini 0 trials
- Pili torti 0 trials
- Trichodysplasia-xeroderma syndrome 0 trials
- Uncombable hair syndrome 0 trials Sub-types →
-
Sebaceous gland disorder 0 trials · 101 incl. sub-types
7 sub-types
- Acne 92 trials Sub-types →
- Internal hordeolum 1 trial · 6 incl. sub-types Sub-types →
- Sebaceous gland neoplasm 0 trials · 3 incl. sub-types Sub-types →
- Alopecia mucinosa 0 trials
- Demodicidosis of sebaceous gland 0 trials
- Rhinophyma 0 trials
- Sebocystomatosis 0 trials
-
Folliculitis 1 trial · 8 incl. sub-types
4 sub-types
- Demodex folliculitis 5 trials
- Acne keloid 1 trial
- Eosinophilic pustular folliculitis 1 trial Sub-types →
- Sycosis barbae 0 trials
-
Hypotrichosis 5 trials · 6 incl. sub-types
19 sub-types
- Hypotrichosis of eyelid 2 trials
- Basaran Yilmaz syndrome 0 trials
- Marie Unna hereditary hypotrichosis 0 trials Sub-types →
- Congenital hypotrichosis milia 0 trials
- Congenital hypotrichosis with juvenile macular dystrophy 0 trials
- Hypotrichosis 1 0 trials
- Hypotrichosis 10 0 trials
- Hypotrichosis 11 0 trials
- Hypotrichosis 12 0 trials
- Hypotrichosis 13 0 trials
- Hypotrichosis 14 0 trials
- Hypotrichosis 15 0 trials
- Hypotrichosis 16 0 trials
- Hypotrichosis 2 0 trials
- Hypotrichosis 3 0 trials
- Hypotrichosis 6 0 trials
- Hypotrichosis 7 0 trials
- Hypotrichosis 8 0 trials
- Hypotrichosis 9 0 trials
-
Piedra 0 trials · 2 incl. sub-types
3 sub-types
- White piedra 2 trials
- Black piedra 0 trials
- Endothrix infectious disease 0 trials
-
Hair follicle neoplasm 0 trials
3 sub-types
- Follicular infundibulum tumor 0 trials
- Pilomatrixoma 0 trials
- Proliferating trichilemmal cyst 0 trials
-
Hypertrichosis 0 trials
11 sub-types
- Rabson-Mendenhall syndrome 0 trials
- Acquired hypertrichosis lanuginosa 0 trials
- Autosomal dominant preaxial polydactyly-upperback hypertrichosis syndrome 0 trials
- Cataract-hypertrichosis-intellectual disability syndrome 0 trials
- Cervical hypertrichosis-peripheral neuropathy syndrome 0 trials
- Gingival fibromatosis-hypertrichosis syndrome 0 trials
- Hypertrichosis cubiti-short stature syndrome 0 trials
- Hypertrichosis lanuginosa congenita 0 trials Sub-types →
- Hypertrichosis of eyelid 0 trials Sub-types →
- Hypertrichosis-acromegaloid facial appearance syndrome 0 trials
- Isolated anterior cervical hypertrichosis 0 trials
-
Trichostasis spinulosa 0 trials
Most studied deeper sub-types
-
Could a higher dose of this pill regrow hair in severe alopecia?
Disease control Recruiting nowThis study tests two daily doses (50 mg and 100 mg) of the medicine ritlecitinib in about 550 people aged 12 and older with severe alopecia areata, a condition causing significant hair loss on the scalp and body. The 50 mg dose is already approved, and researchers want to see if …
Phase 3 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New hope for kids with severe hair loss: baricitinib pill tested in major trial
Disease control Recruiting nowThis study tests whether baricitinib, a daily pill, can safely regrow hair in children aged 6 to 17 with severe alopecia areata (patchy hair loss). About 595 kids will receive either the drug or a placebo for 36 weeks, then all can get the drug for up to 2 years. The goal is to s…
Phase 3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC